Tekmira Pharmaceuticals Stock Rating Reaffirmed by Maxim Group (TKMR)
Tekmira Pharmaceuticals (NASDAQ:TKMR)‘s stock had its “hold” rating reiterated by equities researchers at Maxim Group in a research report issued on Friday. They currently have a $23.00 price objective on the stock. Maxim Group’s target price would suggest a potential upside of 61.18% from the stock’s previous close.
Tekmira Pharmaceuticals (NASDAQ:TKMR) opened at 14.27 on Friday. Tekmira Pharmaceuticals has a one year low of $5.08 and a one year high of $31.48. The stock has a 50-day moving average of $11.84 and a 200-day moving average of $15.66.
Several other analysts have also recently commented on the stock. Analysts at Clarus initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Thursday, July 31st. They set a “buy” rating and a $22.50 price target on the stock. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Tekmira Pharmaceuticals in a research note on Thursday, May 15th. They now have a $31.00 price target on the stock, down previously from $37.00. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $26.63.
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.